Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CPS1 | P31327 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27930766 | 0.85 | CES2 (0.44) | CES2CES1ALDH1A1ALOX15MEP1B | |
| SCHEMBL27189281 | 0.84 | ALDH1A1 (0.41) | CES2CES1ALDH1A1ALOX15MEP1B | |
| SCHEMBL5272363 | 0.83 | ALDH1A1 (0.39) | ALDH1A1ALOX15MEP1BTUBB1MAPT | |
| SCHEMBL116280 | 0.83 | CES2 (0.45) | CES2CES1ALDH1A1MEP1BTUBB1 | |
| SCHEMBL606872 | 0.83 | TDP1 (0.49) | CES2CES1ALDH1A1MEP1BTUBB1 | |
| SCHEMBL201535 | 0.81 | CES2 (0.44) | CES2CES1MEP1BTUBB1MAPT | |
| SCHEMBL3808483 | 0.81 | CES2 (0.48) | CES2CES1ALDH1A1MEP1BMAPT | |
| SCHEMBL27454619 | 0.81 | CTSD (0.47) | CES2CES1ALDH1A1MEP1BMAPT | |
| SCHEMBL525011 | 0.80 | CES2 (0.67) | CES2CES1ALDH1A1ALOX15 | |
| SCHEMBL605762 | 0.79 | ALDH1A1 (0.39) | CES2CES1ALDH1A1ALOX15TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103819401-B | The synthetic method of the fluoro-8-methoxyl group-Isosorbide-5-Nitrae-dihydroquinoline-3-carboxylic acid of 1-cyclopropyl-4-oxo-7- | ZHEJIANG ZHONGXIN FLUORINE MATERIALS CO., LTD. (CN) | 2016-04-13 | — | — | CN | claimed |
| CN-121872929-A | Continuous flow synthesis method and system of nemonoxacin malate intermediate | 四川新迪生物制药有限公司 | 2026-04-17 | — | — | CN | disclosed |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117693511-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-111377826-B | Green synthesis process of key intermediate of quinolone | 浙江本立科技股份有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-111377826-A | Green synthesis process of key intermediate of quinolone | 浙江本立科技股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-8946422-B2 | 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946422-B2 | 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946422-B2 | 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-1913004-A1 | 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | Achillion Pharmaceuticals, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20070049586-A1 | 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049586-A1 | 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049586-A1 | 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2007014308-A1 | 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007014308-A1 | 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20060100436-A1 | Antimicrobial quinolones, their compositions, and uses | WARNER CHILCOTT COMPANY, LLC | 2006-05-11 | — | — | US | disclosed |
| US-6329391-B1 | ANTIBIOTICS, BACTERICIDES USING QUINOLONES | THE PROCTER & GAMBLE CO. | 2001-12-11 | — | — | US | disclosed |
| EP-1015445-A1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999014214-A1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100436-A1 | Antimicrobial quinolones, their compositions, and uses | Q6ZSR9, RECQL, QARS1 | CES2 1712/4885CES1 836/4885ALDH1A1 2880/4885 |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | CES2 496/4885CES1 1813/4885ALDH1A1 2794/4885 |
| US-20070049586-A1 | 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | TOP1, TOP2B, DNA2 | CES2 3232/4885CES1 2987/4885ALDH1A1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.